新辅助化疗治疗Ⅲ期非小细胞肺癌的临床分析

目的探讨新辅助化疗治疗Ⅲ期非小细胞肺癌的临床治疗效果。方法选择2004年10月～2006年10月56例Ⅲ期非小细胞肺癌患者,随机分为观察组和对照组。对照组患者直接行手术治疗。观察组在手术治疗前给予新辅助化疗,具体方案是吉西他滨加顺铂(GP方案)。观察两组患者手术切除率、手术并发症发生情况等。对两组患者进行随访。观察两组患者1年、3年、5年生存率。结果①两组切除率比较,差异有统计学意义(P<0.05)。②两组并发症发生情况比较,差异无统计学意义(P>0.05)。③观察组3年生存率、5年生存率分别与对照组比较,差异有统计学意义(P<0.05)。结论 GP方案新辅助化疗能够提高Ⅲ期非小细胞肺癌手术切除率和长期生存率。临床效果显著。

objective To explore the clinical efficacy of neo-adjuvant chemotherapy on stage Ⅲ non-small cell lung cancer. Methods 56 cases with stage Ⅲ non-small cell lung cancer were selected from October, 2004 to October, 2006. and they were divided into two groups, observation group and control group. Surgical treatment was directly used to control group. Before surgical treatment, neo-adjuvant chemotherapy was given to observation group, the chemotherapy regimen included gemcitabine and cisplatin, resection rate, operative complications in two groups were observed. Follow-up in two groups, one-year survival rate, three years survival rate five years survival rate were observed in two groups. ①Results The resection rate in observation group compared with that in control group, there was statistical difference（P〈0.05）.②The incidence of operative complications in observation group compared with that in control group, there was statistical difference（P〉0.05）.③Three years survival rate and five years survival rate in observation group compared those in control group, there was statistical difference（P〈0.05）.Conclusion Neo-adjuvant chemotherapy can significantly increase resection rate and long term survival rate, the clinical efficacy was significant.